gatifloxacin has been researched along with Tuberculosis, Pulmonary in 15 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Tuberculosis, Pulmonary: MYCOBACTERIUM infections of the lung.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medline, PubMed, Embase, and Cochrane Library were searched with the keyword such as "Levofloxacin," "Moxifloxacin," "Gatifloxacin," and "tuberculosis", through June 1992 to 2017." | 9.22 | The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. ( He, Y; Li, X, 2022) |
| "Medline, PubMed, Embase, and Cochrane Library were searched with the keyword such as "Levofloxacin," "Moxifloxacin," "Gatifloxacin," and "tuberculosis", through June 1992 to 2017." | 5.22 | The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. ( He, Y; Li, X, 2022) |
| "The differences in TB recurrence rates between the G and C arms was statistically significant (p = 0." | 2.78 | Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. ( Balasubramanian, R; Banurekha, VV; Baskaran, D; Chandrasekar, C; Charles, N; Ganapathy, S; Gangadevi, NP; Iliayas, AS; Jagannath, K; Jawahar, MS; Kumar, MM; Kumar, SR; Kumar, V; Mohan, V; Narayanan, PR; Paramasivan, CN; Parthasarathy, RT; Ponnuraja, C; Rahman, F; Ramachandran, R; Raman, B; Sakthivel, MR; Selvakumar, N; Shanmugam, G; Venkatesan, P, 2013) |
| "The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses." | 2.73 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ( Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA, 2008) |
| " However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized." | 2.61 | The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. ( Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS, 2019) |
| "Gatifloxacin has a susceptible dose-dependent zone at MICs 0." | 1.48 | Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. ( Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Gumusboga, M; Koeuth, T; McIlleron, H; Pasipanodya, JG; Smythe, W; Srivastava, S; Thwaites, G; Van Deun, A, 2018) |
| "The number of pulmonary tuberculosis (PTB) patients reported with resistance to first-line anti-tuberculosis drugs after a standardized retreatment regimen in Cameroon is increasing." | 1.38 | Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. ( Abena Foe, JL; Fon, E; Noeske, J; Voelz, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Peloquin, CA | 2 |
| Hadad, DJ | 2 |
| Molino, LP | 1 |
| Palaci, M | 2 |
| Boom, WH | 2 |
| Dietze, R | 2 |
| Johnson, JL | 2 |
| Lenaerts, AJ | 1 |
| Bitting, C | 1 |
| Woolhiser, L | 1 |
| Gruppo, V | 1 |
| Marietta, KS | 1 |
| Johnson, CM | 1 |
| Orme, IM | 1 |
| He, Y | 1 |
| Li, X | 1 |
| Pasipanodya, JG | 2 |
| Smythe, W | 3 |
| Merle, CS | 3 |
| Olliaro, PL | 3 |
| Deshpande, D | 2 |
| Magombedze, G | 1 |
| McIlleron, H | 3 |
| Gumbo, T | 2 |
| Srivastava, S | 1 |
| Bendet, P | 1 |
| Koeuth, T | 1 |
| Bhavnani, SM | 1 |
| Ambrose, PG | 1 |
| Thwaites, G | 1 |
| Gumusboga, M | 1 |
| Van Deun, A | 1 |
| Pranger, AD | 1 |
| van der Werf, TS | 1 |
| Kosterink, JGW | 1 |
| Alffenaar, JWC | 1 |
| Rustomjee, R | 2 |
| Gninafon, M | 2 |
| Lo, MB | 2 |
| Bah-Sow, O | 1 |
| Lienhardt, C | 2 |
| Horton, J | 2 |
| Smith, P | 1 |
| Simonsson, US | 1 |
| Jawahar, MS | 1 |
| Banurekha, VV | 1 |
| Paramasivan, CN | 1 |
| Rahman, F | 1 |
| Ramachandran, R | 1 |
| Venkatesan, P | 1 |
| Balasubramanian, R | 1 |
| Selvakumar, N | 1 |
| Ponnuraja, C | 1 |
| Iliayas, AS | 1 |
| Gangadevi, NP | 1 |
| Raman, B | 1 |
| Baskaran, D | 1 |
| Kumar, SR | 1 |
| Kumar, MM | 1 |
| Mohan, V | 1 |
| Ganapathy, S | 1 |
| Kumar, V | 1 |
| Shanmugam, G | 1 |
| Charles, N | 1 |
| Sakthivel, MR | 1 |
| Jagannath, K | 1 |
| Chandrasekar, C | 1 |
| Parthasarathy, RT | 1 |
| Narayanan, PR | 1 |
| Fielding, K | 1 |
| Sow, OB | 1 |
| Mthiyane, T | 1 |
| Odhiambo, J | 1 |
| Amukoye, E | 1 |
| Bah, B | 1 |
| Kassa, F | 1 |
| N'Diaye, A | 1 |
| de Jong, BC | 1 |
| Perronne, C | 1 |
| Sismanidis, C | 1 |
| Lapujade, O | 1 |
| Warner, DF | 1 |
| Mizrahi, V | 1 |
| Disratthakit, A | 1 |
| Prammananan, T | 1 |
| Tribuddharat, C | 1 |
| Thaipisuttikul, I | 1 |
| Doi, N | 1 |
| Leechawengwongs, M | 1 |
| Chaiprasert, A | 1 |
| Noeske, J | 1 |
| Voelz, N | 1 |
| Fon, E | 1 |
| Abena Foe, JL | 1 |
| Nosova, EY | 1 |
| Bukatina, AA | 1 |
| Isaeva, YD | 1 |
| Makarova, MV | 1 |
| Galkina, KY | 1 |
| Moroz, AM | 1 |
| Daley, CL | 1 |
| Eisenach, KD | 1 |
| Jankus, DD | 1 |
| Debanne, SM | 1 |
| Charlebois, ED | 1 |
| Maciel, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis[NCT00396084] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2004-02-10 | Completed | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| Using Biomarkers to Predict TB Treatment Duration[NCT02821832] | Phase 2 | 946 participants (Actual) | Interventional | 2017-06-21 | Active, not recruiting | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area Under the Curve (AUC) During First 12 or 24 Hours /Minimum Inhibitory Concentration. AUC reflects total drug (bound and unbound). MIC values were determined using protein-containing media. (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 85.6 |
| Levofloxacin 1000 mg/Day | 129.1 |
| Moxifloxacin 400 mg/Day | 110.5 |
| Isoniazid (INH) 300 mg/Day | 215.2 |
Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum colony forming units (cfu) (expressed in log10 units) during the first 2 days of monotherapy. (NCT00396084)
Timeframe: Day 0 to Day 2 Monotherapy
| Intervention | log10 cfu/ml/day (Mean) |
|---|---|
| Gatifloxacin 400 mg/Day | 0.35 |
| Levofloxacin 1000 mg/Day | 0.45 |
| Moxifloxacin 400 mg/Day | 0.33 |
| Isoniazid (INH) 300 mg/Day | 0.67 |
Early bactericidal activity (EBA 0-2) was calculated as the rate of fall in sputum cfu (expressed in log10 units) during the first 2 days of monotherapy. Mean values for the 3 treatment groups were compared. (NCT00396084)
Timeframe: Day 0 to Day 2 Monotherapy
| Intervention | log10 cfu/ml/day (Mean) |
|---|---|
| Isoniazid 300 mg/Day | 0.67 |
| Linezolid 600 mg/Once Daily | 0.18 |
| Linezolid 600 mg/Twice Daily | 0.26 |
The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7. (NCT00396084)
Timeframe: Day 2 to Day 7 Monotherapy
| Intervention | log10 cfu/ml (Mean) |
|---|---|
| Isoniazid 300 mg/Day | 0.16 |
| Linezolid 600 mg/Once Daily | 0.09 |
| Linezolid 600 mg/Twice Daily | 0.04 |
The rate of fall in sputum cfu between day 2 and day 7 of monotherapy was estimated by the slope of the linear regression obtained by fitting the 6 sputum cfu values corresponding to Days 2 through 7. (NCT00396084)
Timeframe: Day 2 to Day 7 Monotherapy
| Intervention | log10 cfu/ml/day (Mean) |
|---|---|
| Gatifloxacin 400 mg/Day | 0.17 |
| Levofloxacin 1000 mg/Day | 0.18 |
| Moxifloxacin 400 mg/Day | 0.17 |
| Isoniazid (INH) 300 mg/Day | 0.08 |
Maximum plasma concentration, given sampling scheme (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 4.8 |
| Levofloxacin 1000 mg/Day | 15.6 |
| Moxifloxacin 400 mg/Day | 6.1 |
| Isoniazid (INH) 300 mg/Day | 3.6 |
Maximum Plasma Drug Concentration (Cmax), given sampling scheme (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Isoniazid 300 mg/Day | 3.3 |
| Linezolid 600 mg/Once Daily | 15.0 |
| Linezolid 600 mg/Twice Daily | 19.4 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 9.5 |
| Levofloxacin 1000 mg/Day | 15.6 |
| Moxifloxacin 400 mg/Day | 12.3 |
| Isoniazid (INH) 300 mg/Day | 70.6 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Isoniazid 300 mg/Day | 62.7 |
| Linezolid 600 mg/Once Daily | 20.0 |
| Linezolid 600 mg/Twice Daily | 16.2 |
Cmax adjusted for free drug concentrations after 5 days of monotherapy with study drugs (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/ml (Median) |
|---|---|
| Isoniazid 300 mg/Day | 3.1 |
| Linezolid 600 mg/Once Daily | 10.3 |
| Linezolid 600 mg/Twice Daily | 13.4 |
Determined by linear extrapolation of concentration-versus-time curve to intersection with MIC. (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | Percentage (Mean) |
|---|---|
| Isoniazid (INH) 300 mg/Day | 95.5 |
| Linezolid 600 mg/Once Daily | 62.8 |
| Linezolid 600 mg/Twice Daily | 100.0 |
Area under the curve (AUC), from time 0-12 hours for INH or 0-24 hours for gatifloxacin, levofloxacin, and moxifloxacin. (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) |
|---|---|
| Gatifloxacin 400 mg/Day | 42.8 |
| Levofloxacin 1000 mg/Day | 129.1 |
| Moxifloxacin 400 mg/Day | 55.3 |
| Isoniazid (INH) 300 mg/Day | 11.9 |
Area Under the Curve 0-12 (AUC 0-12) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC) and AUC 0-24/MIC (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) | |
|---|---|---|
| AUC 0-12/MIC | AUC 0-24/MIC | |
| Isoniazid 300 mg/Day | 306.7 | 344.6 |
| Linezolid 600 mg/Once Daily | 107.8 | 116.2 |
| Linezolid 600 mg/Twice Daily | 121.6 | 243.2 |
Median pharmacodynamic parameters (range) adjusted for free drug concentrations. AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) | |
|---|---|---|
| AUC 0-12 | AUC 0-24 | |
| Isoniazid 300 mg/Day | 15.3 | 17.2 |
| Linezolid 600 mg/Once Daily | 60.1 | 66.8 |
| Linezolid 600 mg/Twice Daily | 80.3 | 160.7 |
Median pharmacokinetic parameters (range). AUC 0-12 and AUC 0-24 = area under the curve during the first 12 and 24 hours after dosing, respectively (NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | ug/h/ml (Median) | |
|---|---|---|
| AUC 0-12 (ug/h/ml) | AUC 0-24 (ug/h/ml) | |
| Isoniazid 300 mg/Day | 17.0 | 19.2 |
| Linezolid 600 mg/Once Daily | 87.0 | 96.9 |
| Linezolid 600 mg/Twice Daily | 116.4 | 232.9 |
The adjusted area under the curve (aAUC) for sputum colony forming unit (cfu) for each day on treatment was calculated for patients in the INH arm and those in the Linezolid once daily and Linezolid twice daily arms. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration. (NCT00396084)
Timeframe: Study drug administration duration - 7 days monotherapy
| Intervention | Percentage (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
| Isoniazid 300 mg/Day | 0.94 | 0.89 | 0.89 | 0.85 | 0.83 | 0.81 | 0.83 |
| Linezolid 600 mg/Once Daily | 0.98 | 0.97 | 0.96 | 0.96 | 0.95 | 0.95 | 0.95 |
| Linezolid 600 mg/Twice Daily | 0.98 | 0.96 | 0.95 | 0.94 | 0.94 | 0.93 | 0.93 |
The adjusted area under the curve (aAUC) for sputum colony forming units (cfu) for each day on treatment was calculated. The aAUC represents the percentage of the expected AUC given no change in log cfu in response to study drug administration. (NCT00396084)
Timeframe: Study drug administration duration - 7 days monotherapy
| Intervention | Percentage (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
| Gatifloxacin 400 mg/Day | 0.98 | 0.96 | 0.92 | 0.89 | 0.87 | 0.85 | 0.82 |
| Isoniazid (INH) 300 mg/Day | 0.95 | 0.90 | 0.87 | 0.84 | 0.81 | 0.80 | 0.80 |
| Levofloxacin 1000 mg/Day | 0.98 | 0.95 | 0.91 | 0.88 | 0.85 | 0.83 | 0.81 |
| Moxifloxacin 400 mg/Day | 0.96 | 0.94 | 0.91 | 0.89 | 0.87 | 0.85 | 0.83 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | hours (Median) | |
|---|---|---|
| Tmax in h (apparent time of max plasma conc.) | Half-life | |
| Isoniazid 300 mg/Day | 1.0 | 3.6 |
| Linezolid 600 mg/Once Daily | 1.5 | 3.20 |
| Linezolid 600 mg/Twice Daily | 1.0 | 4.56 |
(NCT00396084)
Timeframe: Day 5 (7 time points)
| Intervention | hours (Median) | |
|---|---|---|
| Tmax | Half-life | |
| Gatifloxacin 400 mg/Day | 1.5 | 6.0 |
| Isoniazid (INH) 300 mg/Day | 1 | 2.5 |
| Levofloxacin 1000 mg/Day | 1.0 | 7.6 |
| Moxifloxacin 400 mg/Day | 1.0 | 8.1 |
Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Cured | Confirmed relapses | Late withdrawal, lost to follow-up | Probable relapses | Treatment Failure | |
| Arm A | 217 | 5 | 13 | 1 | 1 |
| Arm B | 121 | 1 | 9 | 1 | 0 |
| Arm C | 117 | 9 | 6 | 3 | 4 |
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
2 reviews available for gatifloxacin and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network M | 2022 |
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Treatment | 2019 |
6 trials available for gatifloxacin and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroqui | 2008 |
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Artificial Intelligence; Dose-Response Relationship, Drug; | 2018 |
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa | 2013 |
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination | 2013 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifl | 2006 |
7 other studies available for gatifloxacin and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; | 2008 |
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Lung; Microbial Sensitivity Tests; Monte Carlo Method; | 2018 |
Shortening treatment for tuberculosis--to basics.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Mycobacte | 2014 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extens | 2016 |
Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
Topics: Adult; Antitubercular Agents; Cameroon; Drug Resistance, Multiple, Bacterial; Feasibility Studies; F | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gati | 2013 |
New tuberculosis therapy offers potential shorter treatment.
Topics: Africa; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Fluoroquinolo | 2006 |